ANIMATION

HuLuc 63

Share this article with:

PDL BioPharma asked XVIVO to show how a novel humanized antibody, HuLuc 63, appears to induce anti-tumor effects by binding to a protein expressed only on the surface of myeloma cells. This initiates antibody-dependent cytotoxic activity which targets myeloma cells while leaving healthy cells intact.

Share It:
Contact XVIVO

Client


PDL BioPharma

My experience working with XVIVO can be summed up in one word: Confidence. Confidence in what the quality of the final animation would be, as well as confidence in their recommendations in regard to executing the animation from the initial pre-production meetings throughout the life of the project, until the final delivery. Confidence from the very first day that they would do what they said, when they said they would do it, and deliver high quality multimedia on time, and on budget.

VP, Director of Production, JUICE Pharma Advertising